Skip to main content


  • Meeting abstract
  • Open Access

The effect of carbamylation on the functionality of high-density lipoprotein

  • 1Email author,
  • 2,
  • 3 and
  • 1
BMC Pharmacology20099 (Suppl 2) :A6

  • Published:


  • Cholesterol
  • Atherosclerotic Plaque
  • Atherosclerotic Lesion
  • Lysine Residue
  • Relative Functionality


Increasing interest has focused on the relative functionality of high-density lipoprotein (HDL), highlighted by observations that cardiovascular events can occur even in the presence of high levels of HDL cholesterol. Myeloperoxidase (MPO), a heme protein abundant in leucocytes, colocalizes with HDL in the human artery wall and has emerged as a potential participant in multiple phases of the atherosclerotic process. Recently, the MPO/H2O2/SCN- system has been demonstrated as a dominant pathway to promote protein carbamylation within atherosclerotic plaques. Therefore, we determined whether HDL is carbamylated in the human artery wall.

Methods and results

Immunohistochemical studies confirmed colocalization of carbamylated epitopes with apoA-I and macrophages in human atherosclerotic lesions. We performed shotgun proteomic analysis of in vitro carbamylated HDL to identify specific carbamylation sites of apoA-I. We could identify apoA-I-associated lysine residues in the α-helical lipid binding domains that are specifically carbamylated, indicating that carbamylation of apoA-I affects the functional integrity of HDL. In line with this observation, we observed that carbamylation of HDL (i) leads to "non-productive" binding to the HDL receptor (SR-BI), (ii) decreased SR-BI-mediated cholesterol efflux, and (iii) reduced HDL mediated anti-inflammatory activity.


Taken together, our data provide strong evidence that carbamylation renders HDL dysfunctional and proinflammatory.

Authors’ Affiliations

Institute of Experimental and Clinical Pharmacology, Medical University of Graz, 8010, Graz, Austria
Institute for Cell Biology, Histology and Embryology, Medical University of Graz, 8010, Graz, Austria
Core Facility Mass Spectrometry, Medical University of Graz, 8010, Graz, Austria


© Holzer et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd.